KIDS
OrthoPediatrics Corp
$
17.010
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
17.070
Open
16.360
VWAP
16.84
Vol
174.80K
Mkt Cap
426.57M
Low
16.360
Amount
2.94M
EV/EBITDA(TTM)
--
Total Shares
23.83M
EV
468.18M
EV/OCF(TTM)
--
P/S(TTM)
1.75
OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
68.64M
+12.38%
-0.340
+13.33%
58.73M
+12.06%
-0.295
-35.87%
59.28M
+12.55%
-0.345
-50%
Estimates Revision
The market is revising Downward the revenue expectations for OrthoPediatrics Corp. (KIDS) for FY2025, with the revenue forecasts being adjusted by -2.28% over the past three months. During the same period, the stock price has changed by -9.57%.
Revenue Estimates for FY2025
Revise Downward
-2.28%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.76%
In Past 3 Month
Stock Price
Go Down
-9.57%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast KIDS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KIDS is 24.00 USD with a low forecast of 18.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.010
Low
18.00
Averages
24.00
High
34.00
Current: 17.010
Low
18.00
Averages
24.00
High
34.00
Needham
Needham
Buy
downgrade
$42 -> $26
2025-10-29
Reason
Needham
Needham
Price Target
$42 -> $26
2025-10-29
downgrade
Buy
Reason
Needham lowered the firm's price target on OrthoPediatrics to $26 from $42 and keeps a Buy rating on the shares. The company's Q3 revenue was just above its pre-announcement and adjusted EBITDA missed consensus, the analyst tells investors in a research note. OrthoPediatrics previously indicated that it now expects revenue growth of over 12% over the next few years, and while this is conservative and leaves room for potential upside, the firm is lowering its price target given its lower revenue growth forecasts, Needham added.
Citizens JMP
David Turkaly
Outperform
downgrade
$50 -> $35
2025-08-08
Reason
Citizens JMP
David Turkaly
Price Target
$50 -> $35
2025-08-08
downgrade
Outperform
Reason
Citizens JMP analyst David Turkaly lowered the firm's price target on OrthoPediatrics to $35 from $50 and keeps an Outperform rating on the shares. OrthoPediatrics reported a quarterly record on its top line, though revenues and adjusted EBITDA were shy of consensus, but the company continues to take share in all of its key market segments, and full-year guidance was largely reiterated, the analyst tells investors in a research note. The firm believes the fundamentals around the business remain solid.
BTIG
Buy
maintain
$40 -> $39
2025-08-06
Reason
BTIG
Price Target
$40 -> $39
2025-08-06
maintain
Buy
Reason
BTIG lowered the firm's price target on OrthoPediatrics to $39 from $40 and keeps a Buy rating on the shares after its Q2 results. Trauma & Deformity - T&D - performance was soft in the quarter, but this was offset by an 11.6% beat within Scoliosis, while gross margin and operating margin missed the Street by 170bps and 720bps, the analyst tells investors in a research note.
Truist
Hold
downgrade
$26 -> $22
2025-08-06
Reason
Truist
Price Target
$26 -> $22
2025-08-06
downgrade
Hold
Reason
Truist lowered the firm's price target on OrthoPediatrics to $22 from $26 and keeps a Hold rating on the shares after its Q2 results. The firm continues to like the momentum drivers and ramping profit story for this uniquely positioned asset, but it will take more steady/larger magnitude of beats/raises to support multiple expansion, the analyst tells investors in a research note.
BTIG
Buy
maintain
$38 -> $40
2025-07-14
Reason
BTIG
Price Target
$38 -> $40
2025-07-14
maintain
Buy
Reason
BTIG raised the firm's price target on OrthoPediatrics to $40 from $38 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
Piper Sandler
Matt O'Brien
Overweight
downgrade
$40 -> $30
2025-05-08
Reason
Piper Sandler
Matt O'Brien
Price Target
$40 -> $30
2025-05-08
downgrade
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on OrthoPediatrics to $30 from $40 and keeps an Overweight rating on the shares. The firm notes OrthoPediatrics reported Q1 results which beat soundly on the top-line and gross margins too. Adjusted EBITDA was a little light, but Piper just did not model this metric appropriately and the progress here is completely intact. The firm believes investors need to buy the stock at these levels as management is building a valuable pediatric technology provider that is underappreciated by the market.
See All Ratings
Valuation Metrics
The current forward P/E ratio for OrthoPediatrics Corp (KIDS.O) is -12.84, compared to its 5-year average forward P/E of -44.36. For a more detailed relative valuation and DCF analysis to assess OrthoPediatrics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-44.36
Current PE
-12.84
Overvalued PE
-24.77
Undervalued PE
-63.96
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
279.24
Current EV/EBITDA
19.06
Overvalued EV/EBITDA
710.52
Undervalued EV/EBITDA
-152.04
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
6.25
Current PS
17.01
Overvalued PS
9.58
Undervalued PS
2.92
Financials
Annual
Quarterly
FY2025Q3
YoY :
+12.23%
61.25M
Total Revenue
FY2025Q3
YoY :
-12.58%
-4.87M
Operating Profit
FY2025Q3
YoY :
+48.67%
-11.77M
Net Income after Tax
FY2025Q3
YoY :
+47.06%
-0.50
EPS - Diluted
FY2025Q3
YoY :
-90.67%
-3.42M
Free Cash Flow
FY2025Q3
YoY :
+0.69%
73.92
Gross Profit Margin - %
FY2025Q3
YoY :
-94.44%
-2.23
FCF Margin - %
FY2025Q3
YoY :
+32.46%
-19.22
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
721.7K
USD
5
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
98.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 114.29% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
3.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
45.0K
Volume
Months
0-12
1
21.0K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
721.7K
USD
5
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
98.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KIDS News & Events
Events Timeline
2025-10-28 (ET)
2025-10-28
16:23:52
OrthoPediatrics Announces FDA Approval for 3P Pediatric Plating Platform System
2025-10-28
16:20:57
OrthoPediatrics projects FY25 revenue between $233.5M and $234.5M, below consensus estimate of $235.47M.
2025-10-28
16:19:10
OrthoPediatrics announces Q3 earnings per share of 24 cents, below consensus estimate of 26 cents.
Sign Up For More Events
Sign Up For More Events
News
4.0
11-09Yahoo FinanceWhat Factors Might Influence the OrthoPediatrics Narrative Following Analyst Updates?
4.0
10-29BenzingaUnderstanding OrthoPediatrics: Key Takeaways from 9 Analyst Evaluations
4.0
10-29BenzingaNeedham Keeps Buy Rating on OrthoPediatrics, Reduces Price Target to $26
Sign Up For More News
People Also Watch
PGY
Pagaya Technologies Ltd
24.450
USD
+4.53%
CURV
Torrid Holdings Inc
1.200
USD
+1.69%
EVER
EverQuote Inc
25.430
USD
+2.58%
TTI
Tetra Technologies Inc
7.560
USD
+1.34%
LXU
LSB Industries Inc
8.550
USD
+2.27%
USNA
USANA Health Sciences Inc
19.130
USD
-0.16%
TK
Teekay Corp Ltd
9.730
USD
-0.21%
GES
Guess? Inc
16.960
USD
+0.06%
IMXI
International Money Express Inc
15.140
USD
+0.87%
MNRO
Monro Inc
17.510
USD
+0.46%
FAQ
What is OrthoPediatrics Corp (KIDS) stock price today?
The current price of KIDS is 17.01 USD — it has increased 3.72 % in the last trading day.
What is OrthoPediatrics Corp (KIDS)'s business?
What is the price predicton of KIDS Stock?
What is OrthoPediatrics Corp (KIDS)'s revenue for the last quarter?
What is OrthoPediatrics Corp (KIDS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for OrthoPediatrics Corp (KIDS)'s fundamentals?
How many employees does OrthoPediatrics Corp (KIDS). have?